EDITORIAL

Approving new drugs

+ See all authors and affiliations

Science  24 Feb 2017:
Vol. 355, Issue 6327, pp. 777
DOI: 10.1126/science.aam9914

You are currently viewing the summary.

View Full Text

Summary

As the Trump administration takes shape, there is much speculation as to what major changes will be made. A dominant theme of the Trump campaign was to cut through bureaucracy in Washington, D.C., thereby enhancing innovation and bringing new technology to Americans more quickly. Nowhere could such a philosophical change have more impact than on Food and Drug Administration (FDA) approval of new drugs.